CGEN - Compugen Stock Price, News & Analysis

$2.55 -0.10 (-3.77 %)
(As of 11/23/2017 04:00 PM ET)
Previous Close$2.65
Today's Range$2.55 - $2.70
52-Week Range$2.35 - $6.40
Volume118,900 shs
Average Volume123,913 shs
Market Capitalization$135.50 million
P/E RatioN/A
Dividend YieldN/A
Beta0.62

About Compugen (NASDAQ:CGEN)

Compugen logoCompugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.


Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CGEN
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio6.73%
Quick Ratio6.73%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$710,000.00
Price / Sales183.64
Cash FlowN/A
Price / CashN/A
Book Value$0.74 per share
Price / Book3.45

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($0.71)
Net Income$-31,500,000.00
Net MarginsN/A
Return on Equity-70.91%
Return on Assets-60.92%

Miscellaneous

Employees98
Outstanding Shares51,130,000

Frequently Asked Questions for Compugen (NASDAQ:CGEN)

What is Compugen's stock symbol?

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) issued its quarterly earnings results on Tuesday, August, 2nd. The biotechnology company reported ($0.13) EPS for the quarter, beating the Zacks' consensus estimate of ($0.17) by $0.04. The biotechnology company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $0.11 million. View Compugen's Earnings History.

When will Compugen make its next earnings announcement?

Compugen is scheduled to release their next quarterly earnings announcement on Wednesday, February, 21st 2018. View Earnings Estimates for Compugen.

Where is Compugen's stock going? Where will Compugen's stock price be in 2017?

1 brokerages have issued 1-year target prices for Compugen's stock. Their forecasts range from $14.00 to $14.00. On average, they expect Compugen's share price to reach $14.00 in the next twelve months. View Analyst Ratings for Compugen.

What are Wall Street analysts saying about Compugen stock?

Here are some recent quotes from research analysts about Compugen stock:

  • 1. According to Zacks Investment Research, "Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen's expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. " (10/3/2017)
  • 2. FBR & Co analysts commented, "On February 15, Compugen hosted a conference call to discuss its 4Q16 and FY16 results, and announced that it is searching for a new chairperson for its board of directors to replace its current Chairman Martin Gerstel. We consider the decision benign as Mr. Gerstel’s decision to step down is motivated by his wish to fill the chair with someone who is seasoned in clinical development and commercialization as CGEN draws near to filing its first IND and advancing its own investigational therapy into the clinic. While Mr. Gerstel has successfully led CGEN from using its unique target prediction technologies through discovery of multiple drug targets, we think this decision is logical as CGEN transforms into a clinical-stage company. We look for the first IND filing expected in 4Q17 to be a significant inflection point in the company’s valuation." (2/16/2017)

Who are some of Compugen's key competitors?

Who are Compugen's key executives?

Compugen's management team includes the folowing people:

  • Paul Jai Sekhri, Chairman of the Board (Age 59)
  • Anat Cohen-Dayag Ph.D., President, Chief Executive Officer, Director (Age 48)
  • Ari Krashin, Chief Financial Officer (Age 42)
  • Zurit Levine Ph.D., Vice President - Research and Discovery (Age 47)
  • John Hunter, Vice President - Antibody Research & Development (Age 52)
  • Dov Hershberg, Director (Age 75)
  • Michal Preminger Ph.D., Director
  • Yair Aharonowitz Ph.D., Independent External Director (Age 74)
  • Ruth Arnon, Independent Director (Age 81)
  • Arie Ovadia, Independent External Director (Age 68)

How do I buy Compugen stock?

Shares of Compugen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Compugen's stock price today?

One share of Compugen stock can currently be purchased for approximately $2.55.

How big of a company is Compugen?

Compugen has a market capitalization of $135.50 million and generates $710,000.00 in revenue each year. The biotechnology company earns $-31,500,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis. Compugen employs 98 workers across the globe.

How can I contact Compugen?

Compugen's mailing address is AZRIELI CENTER 26 HAROKMIM STREET BUILDING D, HOLON L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]


MarketBeat Community Rating for Compugen (CGEN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  158 (Vote Outperform)
Underperform Votes:  111 (Vote Underperform)
Total Votes:  269
MarketBeat's community ratings are surveys of what our community members think about Compugen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Compugen (NASDAQ:CGEN)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.00 (449.02% upside)

Consensus Price Target History for Compugen (NASDAQ:CGEN)

Price Target History for Compugen (NASDAQ:CGEN)

Analysts' Ratings History for Compugen (NASDAQ:CGEN)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017FBR & CoSet Price TargetBuy$14.00HighView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$14.00 -> $11.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$14.00 -> $11.00N/AView Rating Details
2/11/2016Jefferies Group LLCReiterated RatingBuy$11.00 -> $9.00N/AView Rating Details
2/1/2016Oppenheimer Holdings, Inc.Reiterated RatingBuyN/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Compugen (NASDAQ:CGEN)

Earnings by Quarter for Compugen (NASDAQ:CGEN)

Earnings History by Quarter for Compugen (NASDAQ CGEN)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2018        
8/2/20176/30/2017($0.17)($0.18)$0.21 millionViewListenView Earnings Details
5/9/20173/31/2017($0.18)($0.17)$0.06 millionViewListenView Earnings Details
2/15/2017Q416($0.18)($0.17)$0.13 million$0.05 millionViewListenView Earnings Details
11/7/2016Q316($0.14)($0.15)$0.41 million$0.07 millionViewN/AView Earnings Details
8/2/2016Q116($0.17)($0.13)$0.11 million$0.50 millionViewN/AView Earnings Details
5/10/2016Q1($0.16)($0.17)$0.12 million$0.09 millionViewListenView Earnings Details
2/9/2016Q415($0.11)($0.01)$3.33 million$8.30 millionViewN/AView Earnings Details
11/3/2015Q315($0.15)($0.13)$0.92 million$0.23 millionViewN/AView Earnings Details
8/4/2015Q215($0.14)($0.14)$1.58 million$0.22 millionViewN/AView Earnings Details
5/5/2015Q115($0.13)($0.12)$1.88 million$0.51 millionViewN/AView Earnings Details
2/10/2015Q414($0.08)($0.03)$3.70 million$6.60 millionViewN/AView Earnings Details
10/29/2014Q314($0.11)($0.11)$1.90 million$1.70 millionViewN/AView Earnings Details
8/6/2014Q214($0.10)($0.07)$1.85 million$2.00 millionViewN/AView Earnings Details
5/19/2014Q114($0.11)($0.04)$0.16 million$2.10 millionViewN/AView Earnings Details
2/11/2014Q413($0.09)$0.13 million$1.80 millionViewN/AView Earnings Details
10/29/2013Q313($0.12)$0.11 million$1.60 millionViewN/AView Earnings Details
11/5/2012Q312($0.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Compugen (NASDAQ:CGEN)
2017 EPS Consensus Estimate: ($0.70)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.18)($0.17)($0.18)
Q2 20172($0.17)($0.17)($0.17)
Q3 20172($0.19)($0.17)($0.18)
Q4 20172($0.18)($0.17)($0.18)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Compugen (NASDAQ:CGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Compugen (NASDAQ CGEN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Compugen (NASDAQ CGEN)

Source:
DateHeadline
Is It Too Late To Buy Compugen Ltd (CGEN)?Is It Too Late To Buy Compugen Ltd (CGEN)?
finance.yahoo.com - November 16 at 12:45 PM
Head-To-Head Survey: Compugen (CGEN) versus Quintiles Transitional Holdings (Q)Head-To-Head Survey: Compugen (CGEN) versus Quintiles Transitional Holdings (Q)
www.americanbankingnews.com - November 8 at 9:31 AM
Compugens (CGEN) CEO Anat Cohen-Dayag on Q3 2017 Results - Earnings Call TranscriptCompugen's (CGEN) CEO Anat Cohen-Dayag on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 7 at 8:08 PM
Compugen Reports Third Quarter 2017 ResultsCompugen Reports Third Quarter 2017 Results
finance.yahoo.com - November 7 at 8:08 PM
Compugen reports 3Q lossCompugen reports 3Q loss
finance.yahoo.com - November 7 at 8:08 PM
Compugen Ltd. to Host Earnings CallCompugen Ltd. to Host Earnings Call
finance.yahoo.com - November 7 at 8:08 PM
Compugen to Initiate Manufacturing of COM902, its Lead Anti-TIGIT Monoclonal AntibodyCompugen to Initiate Manufacturing of COM902, its Lead Anti-TIGIT Monoclonal Antibody
finance.yahoo.com - November 6 at 6:18 PM
ArQule (ARQL) vs. Compugen (CGEN) Head to Head ComparisonArQule (ARQL) vs. Compugen (CGEN) Head to Head Comparison
www.americanbankingnews.com - November 5 at 9:26 AM
Compugen (CGEN) & Its Competitors Head to Head AnalysisCompugen (CGEN) & Its Competitors Head to Head Analysis
www.americanbankingnews.com - November 3 at 5:32 AM
Compugen to Enter Research Collaboration With Mount Sinai on Novel Myeloid Immuno-Oncology TargetsCompugen to Enter Research Collaboration With Mount Sinai on Novel Myeloid Immuno-Oncology Targets
finance.yahoo.com - November 2 at 5:56 PM
Compugen Ltd. (CGEN) Scheduled to Post Quarterly Earnings on TuesdayCompugen Ltd. (CGEN) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 1:56 PM
Compugen to Present at the Annual Meeting of the Society for ... - PR Newswire (press release)Compugen to Present at the Annual Meeting of the Society for ... - PR Newswire (press release)
www.prnewswire.com - October 28 at 12:54 AM
Compugen Third Quarter 2017 Conference Call Scheduled for Tuesday, November 7, 2017 at 10:00 AM ET - PR Newswire (press release)Compugen Third Quarter 2017 Conference Call Scheduled for Tuesday, November 7, 2017 at 10:00 AM ET - PR Newswire (press release)
www.prnewswire.com - October 26 at 8:33 AM
Compugen to Present at the Annual Meeting of the Society for Immunotherapy of Cancer Next MonthCompugen to Present at the Annual Meeting of the Society for Immunotherapy of Cancer Next Month
finance.yahoo.com - October 26 at 8:33 AM
Compugen Third Quarter 2017 Conference Call Scheduled for Tuesday, November 7, 2017 at 10:00 AM ETCompugen Third Quarter 2017 Conference Call Scheduled for Tuesday, November 7, 2017 at 10:00 AM ET
finance.yahoo.com - October 25 at 6:36 PM
Contrasting Compugen (CGEN) and The CompetitionContrasting Compugen (CGEN) and The Competition
www.americanbankingnews.com - October 22 at 12:24 AM
Compugens CGEN-15032 shows potential as immuno-suppressive target in research study, shares ahead 8% premarket - Seeking AlphaCompugen's CGEN-15032 shows potential as immuno-suppressive target in research study, shares ahead 8% premarket - Seeking Alpha
seekingalpha.com - October 11 at 6:39 PM
Corporate News Blog - Compugen Announces New Data Indicating Potential of CGEN-15032Corporate News Blog - Compugen Announces New Data Indicating Potential of CGEN-15032
finance.yahoo.com - October 11 at 6:39 PM
Compugen (CGEN) Says New Immunomodulatory Target Demonstrates Potential for First-in-Class Cancer Therapy - StreetInsider.comCompugen (CGEN) Says New Immunomodulatory Target Demonstrates Potential for First-in-Class Cancer Therapy - StreetInsider.com
www.streetinsider.com - October 9 at 5:47 PM
A New Immunomodulatory Target Discovered by Compugen Demonstrates Potential for First-in-Class Cancer TherapyA New Immunomodulatory Target Discovered by Compugen Demonstrates Potential for First-in-Class Cancer Therapy
finance.yahoo.com - October 9 at 5:47 PM
Flexion Shares Continue Rise After FDA Approval -- Biotech MoversFlexion Shares Continue Rise After FDA Approval -- Biotech Movers
finance.yahoo.com - October 9 at 5:47 PM
Compugen Ltd (CGEN): How Does It Impact Your Portfolio?Compugen Ltd (CGEN): How Does It Impact Your Portfolio?
finance.yahoo.com - October 2 at 4:28 PM
Financial Review: Incyte Corporation (INCY) versus Compugen (CGEN)Financial Review: Incyte Corporation (INCY) versus Compugen (CGEN)
www.americanbankingnews.com - September 16 at 2:30 AM
Compugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next MonthCompugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Month
finance.yahoo.com - August 7 at 5:32 PM
Q3 2017 EPS Estimates for Compugen Ltd. (NASDAQ:CGEN) Reduced by Jefferies GroupQ3 2017 EPS Estimates for Compugen Ltd. (NASDAQ:CGEN) Reduced by Jefferies Group
www.americanbankingnews.com - August 4 at 8:30 AM
Compugen Ltd. (CGEN) Posts Quarterly  Earnings Results, Misses Estimates By $0.01 EPSCompugen Ltd. (CGEN) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - August 3 at 8:08 PM
Compugen (CGEN) Announces Paul Sekhri as New Chairman of the Board - StreetInsider.comCompugen (CGEN) Announces Paul Sekhri as New Chairman of the Board - StreetInsider.com
www.streetinsider.com - August 3 at 6:36 PM
Compugens (CGEN) CEO Anat Cohen-Dayag on Q2 2017 Results - Earnings Call TranscriptCompugen's (CGEN) CEO Anat Cohen-Dayag on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 2 at 5:54 PM
Compugen (CGEN) Announces Paul Sekhri as New Chairman of the BoardCompugen (CGEN) Announces Paul Sekhri as New Chairman of the Board
www.streetinsider.com - August 2 at 5:54 PM
Compugen Reports Second Quarter 2017 ResultsCompugen Reports Second Quarter 2017 Results
finance.yahoo.com - August 2 at 5:54 PM
Compugen Welcomes Paul Sekhri as its New Chairman of the BoardCompugen Welcomes Paul Sekhri as its New Chairman of the Board
finance.yahoo.com - August 2 at 5:54 PM
Compugen reports 2Q lossCompugen reports 2Q loss
finance.yahoo.com - August 2 at 5:54 PM
 Brokerages Expect Compugen Ltd. (CGEN) Will Announce Earnings of -$0.17 Per Share Brokerages Expect Compugen Ltd. (CGEN) Will Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - July 28 at 10:24 PM
BRIEF-Compugen discloses updates to collaborative activities with Bayer in immuno-oncologyBRIEF-Compugen discloses updates to collaborative activities with Bayer in immuno-oncology
www.reuters.com - July 28 at 2:38 AM
Compugen (CGEN) Reprts Updates to Collaborative Activities with Bayer in Immuno-OncologyCompugen (CGEN) Reprts Updates to Collaborative Activities with Bayer in Immuno-Oncology
www.streetinsider.com - July 28 at 2:38 AM
BUZZ-US STOCKS ON THE MOVE- Boeing, AMD, Akamai, Corning - NasdaqBUZZ-US STOCKS ON THE MOVE- Boeing, AMD, Akamai, Corning - Nasdaq
www.nasdaq.com - July 27 at 9:37 PM
Compugen Ltd. (CGEN) Set to Announce Quarterly Earnings on WednesdayCompugen Ltd. (CGEN) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 27 at 9:59 AM
Compugen (CGEN) Reprts Updates to Collaborative Activities with ... - StreetInsider.comCompugen (CGEN) Reprts Updates to Collaborative Activities with ... - StreetInsider.com
www.streetinsider.com - July 26 at 5:39 PM
Compugen Discloses Updates to Collaborative Activities with Bayer in Immuno-OncologyCompugen Discloses Updates to Collaborative Activities with Bayer in Immuno-Oncology
finance.yahoo.com - July 26 at 5:39 PM
Compugen (CGEN) Receives US Patent for COM701 - StreetInsider.comCompugen (CGEN) Receives US Patent for COM701 - StreetInsider.com
www.streetinsider.com - July 25 at 5:07 PM
Compugen Announces Issuance of U.S. Patent for COM701, its Lead Immuno-Oncology Product CandidateCompugen Announces Issuance of U.S. Patent for COM701, its Lead Immuno-Oncology Product Candidate
finance.yahoo.com - July 25 at 5:06 PM
Compugen Second Quarter 2017 Conference Call Scheduled for Wednesday, August 2, 2017 at 10:00 AM ETCompugen Second Quarter 2017 Conference Call Scheduled for Wednesday, August 2, 2017 at 10:00 AM ET
finance.yahoo.com - July 24 at 11:40 AM
$210,000.00 in Sales Expected for Compugen Ltd. (CGEN) This Quarter$210,000.00 in Sales Expected for Compugen Ltd. (CGEN) This Quarter
www.americanbankingnews.com - July 6 at 10:04 AM
Compugen Ltd. (NASDAQ:CGEN) Expected to Post Earnings of -$0.17 Per ShareCompugen Ltd. (NASDAQ:CGEN) Expected to Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - July 4 at 6:20 PM
Compugen (CGEN) Reports COM701 Drug Combination Data with TIGIT and PD-1 Inhibitors in Preclinical Models at ... - StreetInsider.comCompugen (CGEN) Reports COM701 Drug Combination Data with TIGIT and PD-1 Inhibitors in Preclinical Models at ... - StreetInsider.com
www.streetinsider.com - June 6 at 4:27 PM
Compugen provides update on COM701 and upcoming ... - Seeking AlphaCompugen provides update on COM701 and upcoming ... - Seeking Alpha
seekingalpha.com - May 31 at 9:31 PM
Compugen (CGEN) Appoints Michal Preminger to Board of Directors - StreetInsider.comCompugen (CGEN) Appoints Michal Preminger to Board of Directors - StreetInsider.com
www.streetinsider.com - May 25 at 5:43 PM
Compugen (CGEN) Appoints Michal Preminger to Board of Directors - StreetInsider.comCompugen (CGEN) Appoints Michal Preminger to Board of Directors - StreetInsider.com
www.streetinsider.com - May 25 at 5:43 PM
Compugen Reports First Quarter 2017 Results - PR Newswire (press release)Compugen Reports First Quarter 2017 Results - PR Newswire (press release)
www.prnewswire.com - May 10 at 8:25 AM
Compugen to Present COM701 Checkpoint Product Candidate for Immuno-Oncology at ASCO - PR Newswire (press release)Compugen to Present COM701 Checkpoint Product Candidate for Immuno-Oncology at ASCO - PR Newswire (press release)
www.prnewswire.com - May 6 at 6:40 AM

Social Media

Financials

Chart

Compugen (NASDAQ CGEN) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.